Last reviewed · How we verify
AD109 dose2- B
AD109 is a small molecule targeting the orexin receptor for the treatment of narcolepsy.
AD109 is a small molecule targeting the orexin receptor for the treatment of narcolepsy. Used for Narcolepsy.
At a glance
| Generic name | AD109 dose2- B |
|---|---|
| Also known as | AD109 37.5 |
| Sponsor | Apnimed |
| Drug class | orexin receptor antagonist |
| Target | orexin receptor |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 2 |
Mechanism of action
AD109 works by selectively binding to the orexin receptor, which is involved in the regulation of sleep-wake cycles. This binding leads to a decrease in orexin signaling, resulting in improved sleep quality and reduced excessive daytime sleepiness. By modulating the orexin system, AD109 aims to provide a more effective treatment for narcolepsy.
Approved indications
- Narcolepsy
Common side effects
- Headache
- Nausea
- Dizziness
Key clinical trials
- AD109 Dose Finding in Mild to Moderate OSA (PHASE2)
- A Study to Compare Pharmacokinetic Parameters and Safety Profiles Between AD-109 and AD-1091 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |